Reduce healthcare costs with innovative precision medicine for musculoskeletal pain
Delivers greater than 3:1 ROI on musculoskeletal care costs while reducing the need for elective total knee surgery by up to 89%
Apos® is precision medicine for musculoskeletal pain
A targeted innovative approach to addressing knee osteoarthritis, chronic hip and non-specific back pain. By considering each patient’s unique anatomy, biomechanics, neuromuscular responses, and medical history, Apos® delivers personalized treatment tailored to individual needs. As easy to use as putting on a pair of reading glasses, it significantly improves pain relief, functional ability, and quality of life.
Health plans trust Apos® to lower MSK management costs
Independent reviews of real-world claims data across Medicaid, Medicare Advantage, and Commercial populations reveal an ROI of over 3:1 within the first year of implementation. In one study, Apos® saved an average of $3,689 per patient, substantially reducing healthcare expenses for a commercial payor.
Reduction in healthcare utilization
Apos® led to a 43% reduction in healthcare services, including imaging, injections, pain medications, and specialty visits.
Clinical benefits & cost savings
Significant reductions in healthcare costs for patients, insurers, and providers.
Reduction in diagnostic claims
Decrease in outpatient services
Decrease in non-operative treatments
Decrease in pain medications:
Reduction in opioid use
Decrease in intra-articular injections
Reduction in diagnostic claims
Decrease in outpatient services
Decrease in non-operative treatments
Decrease in pain medications:
Reduction in opioid use
Decrease in intra-articular injections
Explore the full study:
Reduction in Healthcare Resource Utilization Following Treatment With a Home-Based Footworn Device in Patients With Knee Osteoarthritis: A Retrospective Claims Analysis
Deliver high member satisfaction with treatment that works
After treating more than 150,000 patients and based on 15 years of research and development, the results of Apos® speak for themselves
After treatment, Apos® patients…
Have
Better function1
(on average)
Experience
Less pain1
(on average)
Report a
Satisfaction
rate2
Can walk
Faster3
Use
Less
painkillers4
Before and after Apos®
Explore over 70 clinical publications
What our patients say
“The first day I tried them, I cried—because I could walk normally again.”
- Robert L.
Former marathon runner with chronic knee pain
“Now I can jog as fast as I would normally jog.”
- George T.
FDNY employee who had chronic back pain
“Thanks to Apos® I’m able to ride horses, ski, and dance again.”
– Jonquille S.
Broke femur bone in horse-riding accident
Choose an MSK solution that’s meaningful for you and your members
Contact us to improve your MSK results while reducing costs
FAQs
Apos® reduces the need for expensive surgeries, injections, and treatments while improving employee health, leading to better ROIs. A recent study showed 43% reduction in MSK management costs within one year of implementation.
Unlike traditional approaches, Apos® uses advanced gait science to retrain how patients walk, addressing both the symptoms and underlying causes of pain—all from the comfort of home or the office.
Our approach is backed by over 70 peer-reviewed clinical publications, including a recent study showing that 89% of eligible total knee replacement patients avoided surgery for up to 6 years with Apos®.
Apos® is FDA cleared for treating knee osteoarthritis and FDA registered and evidence backed for chronic hip pain and non-specific lower back pain, offering personalized treatment for each patient’s needs.
Many feel relief right away as the device helps realign their joints. For others, it may take 3-6 months. Long-term relief happens because, over time, the muscles learn to stabilize the joints better, even when they are not wearing the device.
Yes, studies show that Apos® can reduce the need for total knee replacement surgery by up to 89%.
Sources
- Reichenbach et al., JAMA (2020): 70% pain reduction with Apos® vs. 35% in controls.
- NHS UK survey: 98% would recommend Apos®.
- Sorin, A., et al. (2020). BMC Musculoskelet Disord. 21:846.
- Bar-Ziv Y, et al. (2010). BMC Musculoskelet Disord. 11:179.
- Benn, R., et al. (2023). Ther. Adv. Musculoskelet. Dis.